期刊文献+

聚合酶链反应/变性高效液相色谱技术检测载脂蛋白E基因型 被引量:1

Detection of apolipoprotein E genotype by denaturing high performance liquid chromatography and polymerase chain reaction
下载PDF
导出
摘要 目的建立快速检测载脂蛋白E(apoE)基因型的变性高效液相色谱技术。方法标准酚-氯仿法提取180份健康人外周血基因组DNA,用聚合酶链反应/变性高效液相色谱(PCR/DHPLC)技术测定apoE基因型,分析人群中apo E基因型和等位基因的分布频率。结果共检出6种基因型:ε3/ε3占73.89%,ε2/ε3和ε3/ε4各占15.56%和7.22%,ε2/ε2、ε2/ε4和ε4/ε4共占3.34%。3种等位基因中,最常见的是ε3,占85.28%,ε2和ε4各占10.00%和4.72%。结论建立了一种基于DHPLC的apo E基因分型方法,该方法具有简便、准确的特点。 Objective To develop a genotyping assay for detection of apolipoprotein E(apo E) genotype by using denaturing high performance liquid chromatography(DHPLC) and polymerase chain reaction(PCR).Methods Genome DNA samples of 180 healthy subjects were extracted by phenol-chloroform method from peripheral blood.Genotyping assay was developed by PCR/DHPLC to detect the genotypes of apo E gene.Results Among the 6 genotypes determined from the 180 subjects,the most common genotype was ε3/ε3 with frequency of 73.89%,followed by ε2/ε3 and ε3/ε4 with frequency of 15.56% and 7.22% respectively.The total frequency of ε2/ε2,ε2/ε4 and ε4/ε4 was 3.34%.The most common allele was ε3 with frequency of 85.28%,while ε2 and ε4 allele were 10.00% and 4.72% respectively.Conclusion The DHPLC assay developed is simple and accurate for detection of apoE genotype.
出处 《临床检验杂志》 CAS CSCD 北大核心 2011年第1期40-42,共3页 Chinese Journal of Clinical Laboratory Science
基金 贵州省科技厅基金资助项目(黔科合J字[2008]2296号)
关键词 载脂蛋白E 基因多态性 变性高效液相色谱 apolipoprotein E gene polymorphism denaturing high performance liquid chromatography
  • 相关文献

参考文献5

  • 1黎旭,赵冬,刘静,刘飒,刘军,秦兰萍,吴兆苏.北京自然人群载脂蛋白E基因多态性频率分布研究[J].首都医科大学学报,2003,24(3):268-271. 被引量:13
  • 2孙丽娜,张波,许颖,周晓星,黄莉莉,卓淑雨,苏宜香.广州市40~65岁居民载脂蛋白E基因多态性与血脂水平的关系[J].中山大学学报(医学科学版),2008,29(2):181-185. 被引量:5
  • 3Pedersen JC, Berg K. Gene-gene interaction between the low density lipoprotein receptor and apolipoprotein E loci affects lipid levels[ J]. Clin Genet, 1990,38 (4) : 287-294.
  • 4Eggertsen G, Tegelman R, Ericsson S, et al. Apolipoprotein E polymorphism in a healthy Swedish population: variation of allele frequency with age and relation to serum lipid concentrations [ J ]. Clin Chem, 1993,39(10) :2125-2129.
  • 5Zeng Y, Miao F, Li L, et al. A rapid and accurate DHPLC assay for determination of apolipoprotein E gcnotypes [J]. J Alzheimers Dis, 2007,12(4) :357-363.

二级参考文献22

  • 1中国居民营养与健康现状[J].中国心血管病研究,2004,2(12):919-922. 被引量:495
  • 2梁茜,董吁钢,杨希立,杨光,崔金环.血管紧张素转换酶、内皮型一氧化氮合酶和载脂蛋白E基因多态性与冠心病的相关性[J].中山大学学报(医学科学版),2006,27(4):396-400. 被引量:7
  • 3王克勤 解用虹 等.中国人群(京津地区)载脂蛋白E基因多态性和表型分布的研究[J].生物化学杂志,1988,4(3):274-274.
  • 4Ordovas J M, Litwack-Klein L, Wilson P W F, et al. Apolipoprotein E isoform phnotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. J Lipid Res, 1987,28 : 371 - 380.
  • 5Wermann G, Sfeinmetfz A, Weber W. Genetic control of human apolipoprotein E polymorphism comparison of one-and-two-dimensional techniques of isoprotein analysis. Hum Genet, 1982, 60:334- 351.
  • 6Ehnhlm C, Lukka M, Kuusi T, et al. Apoliporotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentration. J Lipid Res, 1986,27:227-235.
  • 7Eggertsen G, Tegelman R, Ericsson S, et al. Applipoprotein E polymorphism in a healthy Swedish population: variation of allele frequency with age and relation to serum lipid concentration. Clin Chem, 1993,39:2125.
  • 8Eto M, Watanabe K, Ishii K. Reciprocal effects of apolipoprotein E alleles (ε2 and ε4) on plasma lipid levels in normolipidemic subjects. Clin Genet, 1986,29:477-484.
  • 9Donohoe G G, Salomalki A, Lehtimalki T, et al. Rapid identification of Apolipoprotein E genotypes by Multiplex Amplification Refractory Mutation System PCR and Capillary Gel Electrophoresis [J]. Clin Chem, 1999, 45:143-145.
  • 10Newton C R, Graham A, Heptinstall L E, et al. Analysis of any point mutation in DNA. The amplication refractory mutation system (ARMS) [J]. Nucleic Acids Res, 1989, 17: 2503-2516.

共引文献16

同被引文献18

  • 1Yu HC, Chan TY, Critchely JA, et al. Factors determining the maintenance dose of warfarin in Chinese patients. QJM, 1996, 89:127-135.
  • 2Chenhsu RY, Chiang SC, Chou MH, et al. Long-term treatment with warfarin in Chinese population. Ann Pharmacother, 2000, 34 : 1395-1401.
  • 3Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J, 2003, 3: 202-214.
  • 4Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 5Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 2005,106 : 2329-2933.
  • 6Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics, 2009, 19: 226-234.
  • 7Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 8Yu BN, Luo CH, Wang D, et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta, 2004,348:57-61.
  • 9Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmaeogenomics J, 2005, 5: 262-270.
  • 10Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet, 2007,121:23-34.

引证文献1

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部